Botulinum toxin

Plastic and Reconstructive Surgery

Volumn 112, Issue 5 SUPPL., 2003, Pages

  Matarasso, Alan ^a   Chia, Christopher ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; MUSCLE RELAXANT AGENT;

ARTICLE; BIOEQUIVALENCE; CLOSTRIDIUM BOTULINUM; DRUG MECHANISM; ESTHETIC SURGERY; HUMAN; PARALYSIS; PRIORITY JOURNAL; WRINKLE; FOLLOW UP;

BOTULINUM TOXIN TYPE A; COSMETIC TECHNIQUES; FOLLOW-UP STUDIES; HUMANS; NEUROMUSCULAR AGENTS;

EID: 0142186663     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000082194.99195.66     Document Type: Article

References (21)

1. van Ermengem, E. Classics in infectious disease: A new anaerobic bacillus and its relation to botulism. Rev. Infect. Dis. 1: 701, 1979.
2. Scott, A. B., Rosenbaum, A., and Collins, C. C. Pharmacologic weakening of the extraocular muscles. Invest. Ophthalmol. 12: 924, 1973.
3. Clark, R. P., and Berris, C. E. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis. Plast. Reconstr. Surg. 84: 353, 1989.
4. Brin, M. F. Botulinum toxin: New and expanded indications. Eur. J. Neurol. 4 (Suppl.): S59, 1997.
5. Huang, W., Foster, J. A., and Rogachefsky, A. S. Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. 43: 249, 2000.
6. Ramirez, A. L., Reeck, J., and Maas, C. S. Botulinum toxin type B (Myobloc) in the management of hyperkinetic facial lines. Otolaryngol. Head Neck Surg. 126: 459, 2002.
7. Humeau, Y., Doussau, F., Grant, N. J., and Poulain, B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82: 427, 2000.
8. Brin, M. F. The pharmacology of botulinum toxin. Muscle Nerve 6 (Suppl.): S146, 1997.
9. Li, L., Binz, T., Niemann, H., et al. Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain. Biochemistry 39: 2399, 2000.
10. Matarasso, S. L. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol. Surg. 24: 1232, 1998.
11. Lowe, N. J. Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives. Dermatol. Surg. 24: 1216, 1998.
12. Pasricha, P. J., Ravich, W. J., Hendrix, T. R., Sostre, S., Jones, B., and Kalloo, A. N. Intrasphincteric botulinum toxin for the treatment of achalasia. N. Engl. J. Med. 332: 774, 1995
13. (published erratum in N. Engl. J. Med. 333: 75, 1005).
14. Glickman, S., and Deaney, C. N. Treatment of relative sialorrhea with botulinum toxin type A: Description and rationale for an injection procedure with case report. Eur. J. Neurol. 8: 567, 2001.
15. Miller, L. S., Szych, G. A., Kantor, S. B., et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am. J. Gastroenterol. 97: 1653, 2002.
16. Maria, G., Cassetta, E., Gui, D., Brisinda, G., Bentivoglio, A. R., and Albanese, A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N. Engl. J. Med. 338: 217, 1998.
17. Matarasso, S. L. Wound healing and botulinum toxin in Mohs surgery, personal communication, 2002.
18. Carruthers, A., and Carruthers, J. Clinical indications and injection technique for the cosmetic use of botulinum A toxin. Dermatol. Surg. 24: 1189, 1998.
19. Fulton, J. E. Botulinum toxin: The Newport Beach experience. Dermatol. Surg. 24: 1219, 1998.
20. Carruthers, J., and Carruthers, A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects. Dermatol. Surg. 29: 802, 2003.
21. Fagien, S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: Adjunctive use in racial aesthetic surgery. Plast. Reconstr. Surg. 103: 701, 1999.